AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.
During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.
AbbVie exploits the U.S. patent system to push up prices for the company’s Humira rheumatoid arthritis drug and cancer medicine Imbruvica, according to a U.S. House of Representatives Oversight Committee staff report on May 18.
A legal complaint was filed against Alvotech for the Icelandic pharmaceutical company’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.
UCB SA said the company’s experimental plaque psoriasis drug bimekizumab produced better results compared to AbbVie Inc.’s blockbuster medicine Humira in reducing the disease’s severity.